thymine has been researched along with Adverse Drug Event in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf®), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age." | 9.27 | Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. ( Cohen, SJ; Grothey, A; Hochster, HS; Makris, L; Mayer, RJ; Winkler, R, 2018) |
| "Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC)." | 7.96 | Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. ( Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020) |
| "Trifluridine/tipiracil (TAS-102, Lonsurf®), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies." | 7.88 | Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer. ( Fuchs, M; Karthaus, M; Kasper, S; Kisro, J; Müller, C; Rafiyan, MR; Schulz-Abelius, A; Stein, A, 2018) |
| "Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies." | 7.83 | Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. ( Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016) |
| "Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf®), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age." | 5.27 | Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. ( Cohen, SJ; Grothey, A; Hochster, HS; Makris, L; Mayer, RJ; Winkler, R, 2018) |
| "Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC)." | 3.96 | Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. ( Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020) |
| "Trifluridine/tipiracil (TAS-102, Lonsurf®), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies." | 3.88 | Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer. ( Fuchs, M; Karthaus, M; Kasper, S; Kisro, J; Müller, C; Rafiyan, MR; Schulz-Abelius, A; Stein, A, 2018) |
| "Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies." | 3.83 | Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. ( Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mayer, RJ | 1 |
| Hochster, HS | 1 |
| Cohen, SJ | 1 |
| Winkler, R | 1 |
| Makris, L | 1 |
| Grothey, A | 1 |
| Kasper, S | 1 |
| Kisro, J | 1 |
| Fuchs, M | 1 |
| Müller, C | 1 |
| Schulz-Abelius, A | 1 |
| Karthaus, M | 1 |
| Rafiyan, MR | 1 |
| Stein, A | 1 |
| Fernandez Montes, A | 1 |
| Vazquez Rivera, F | 1 |
| Martinez Lago, N | 1 |
| Covela Rúa, M | 1 |
| Cousillas Castiñeiras, A | 1 |
| Gonzalez Villarroel, P | 1 |
| de la Cámara Gómez, J | 1 |
| Méndez Méndez, JC | 1 |
| Salgado Fernández, M | 1 |
| Candamio Folgar, S | 1 |
| Reboredo López, M | 1 |
| Carmona Campos, M | 1 |
| Gallardo Martín, E | 1 |
| Jorge Fernández, M | 1 |
| Pellón Augusto, ML | 1 |
| París Bouzas, L | 1 |
| García Gómez, J | 1 |
| Sueda, T | 1 |
| Sakai, D | 1 |
| Kudo, T | 1 |
| Sugiura, T | 1 |
| Takahashi, H | 1 |
| Haraguchi, N | 1 |
| Nishimura, J | 1 |
| Hata, T | 1 |
| Hayashi, T | 1 |
| Mizushima, T | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Satoh, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy[NCT02286492] | 0 participants | Expanded Access | Approved for marketing | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thymine and Adverse Drug Event
| Article | Year |
|---|---|
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Respon | 2018 |
3 other studies available for thymine and Adverse Drug Event
| Article | Year |
|---|---|
Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Compassionate Use Trials; Drug-Related Side Effec | 2018 |
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Drug-Related Side Effects a | 2020 |
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Drug | 2016 |